for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boston Scientific Corporation

BSX.N

Latest Trade

34.55USD

Change

-0.09(-0.26%)

Volume

2,107,110

Today's Range

34.20

 - 

34.72

52 Week Range

24.10

 - 

46.25

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
34.64
Open
34.67
Volume
2,107,110
3M AVG Volume
240.42
Today's High
34.72
Today's Low
34.20
52 Week High
46.25
52 Week Low
24.10
Shares Out (MIL)
1,428.69
Market Cap (MIL)
50,847.20
Forward P/E
37.63
Dividend (Yield %)
--

Next Event

Q2 2020 Boston Scientific Corp Earnings Call

Latest Developments

More

Boston Scientific Says Entered Into Second Amendment To $1 Billion 364-Day Term Loan Credit Agreement

Boston Scientific Prices Offerings Of Common Stock, Mandatory Convertible Preferred Stock

Boston Scientific Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Industry

Medical Equipment & Supplies

Contact Info

300 BOSTON SCIENTIFIC WAY

MARLBOROUGH, MA

01752-1234

United States

+1.508.6834000

https://www.bostonscientific.com/

Executive Leadership

Michael F. Mahoney

Chairman of the Board, President, Chief Executive Officer

Daniel J. Brennan

Chief Financial Officer, Executive Vice President

Arthur C. Butcher

Executive Vice President and President, Asia Pacific

Joseph M. Fitzgerald

Executive Vice President, President, Interventional Cardiology

Edward F. Mackey

Executive Vice President - Operations

Key Stats

1.64 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

9.0K

2018

9.8K

2019

10.7K

2020(E)

9.7K
EPS (USD)

2017

1.260

2018

1.470

2019

1.580

2020(E)

0.965
Price To Earnings (TTM)
271.00
Price To Sales (TTM)
4.71
Price To Book (MRQ)
3.61
Price To Cash Flow (TTM)
40.87
Total Debt To Equity (MRQ)
74.87
LT Debt To Equity (MRQ)
67.60
Return on Investment (TTM)
0.81
Return on Equity (TTM)
0.68

Latest News

Latest News

BRIEF-Boston Scientific Corp - Kevin Ballinger Resigning To Take CEO Position At Co That Does Not Compete With Boston Scientific

* BOSTON SCIENTIFIC CORP - KEVIN BALLINGER RESIGNING TO TAKE CEO POSITION AT CO THAT DOES NOT COMPETE WITH BOSTON SCIENTIFIC Source text for Eikon: https://bit.ly/2XLd0hW Further company coverage:

BRIEF-Boston Scientific Receives Medicare Transitional Pass-Through Payment For The Exalt Model D Single-Use Duodenoscope

* BOSTON SCIENTIFIC RECEIVES MEDICARE TRANSITIONAL PASS-THROUGH PAYMENT FOR THE EXALT™ MODEL D SINGLE-USE DUODENOSCOPE Source text for Eikon: Further company coverage:

BRIEF-Boston Scientific Launches Directsense Technology

* BOSTON SCIENTIFIC LAUNCHES DIRECTSENSE™ TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Boston Scientific Says Entered Into Second Amendment To $1 Billion 364-Day Term Loan Credit Agreement

* BOSTON SCIENTIFIC - ON MAY 28 ENTERED INTO SECOND AMENDMENT TO ITS $1 BILLION 364-DAY TERM LOAN CREDIT AGREEMENT

BRIEF-Boston Scientific Prices Offerings Of Common Stock, Mandatory Convertible Preferred Stock

* BOSTON SCIENTIFIC PRICES OFFERINGS OF COMMON STOCK AND MANDATORY CONVERTIBLE PREFERRED STOCK

Fitch Ratings: Boston Scientific's Ratings Unaffected by Equity Issuance

Fitch Ratings-Austin-May 21: Boston Scientific Corp.'s (BSX) announced offerings of both common and preferred stock will provide additional liquidity as the company experiences near-term operational pressures from the coronavirus pandemic, according to Fitch Ratings. Proceeds...

BRIEF-Boston Scientific Files For Potential Stock Shelf Offering Size Not Disclosed

* BOSTON SCIENTIFIC CORP FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/2yiW4FJ) Further company coverage:

BRIEF-Boston Scientific Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

* BOSTON SCIENTIFIC ANNOUNCES OFFERINGS OF COMMON STOCK AND MANDATORY CONVERTIBLE PREFERRED STOCK

BRIEF-Sonova Holding: Advanced Bionics Awarded Damages In Patent Infringement Lawsuit

* SONOVA HOLDING AG SAYS ADVANCED BIONICS AWARDED DAMAGES IN PATENT INFRINGEMENT LAWSUIT

BRIEF-Boston Scientific Completes $1.7 Billion Offering Of Senior Notes

* BOSTON SCIENTIFIC COMPLETES $1.7 BILLION OFFERING OF SENIOR NOTES Source text for Eikon: Further company coverage:

BRIEF-Boston Scientific Prices $1.7 Billion Of Senior Notes

* BOSTON SCIENTIFIC - PUBLIC OFFERING CONSISTS OF $500.0 MILLION OF 1.900% NOTES DUE 2025 AND $1.2 BILLION OF 2.650% NOTES DUE 2030 Source text for Eikon: Further company coverage:

Fitch Rates Boston Scientific's Unsecured Notes 'BBB'

Fitch Ratings has assigned a 'BBB' rating to Boston Scientific Corp.'s unsecured notes issuance. The transaction is expected to be leverage neutral. The ratings are supported by the strength of Boston Scientific's operational profile, improving FCF profile and liquidity...

BRIEF-Boston Scientific Files Prospectus Supplement Related To Potential Two-Part Senior Notes Offering

* BOSTON SCIENTIFIC CORP FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART SENIOR NOTES OFFERING - SEC FILING Source: (https://bit.ly/2T6DSX0) Further company coverage:

BRIEF-Pinnacle FLX Study Of The Watchman FLX™ Left Atrial Appendage Closure Device Presented As Late-Breaking Clinical Trial At HRS 2020 Science

* PINNACLE FLX STUDY OF THE WATCHMAN FLX™ LEFT ATRIAL APPENDAGE CLOSURE DEVICE PRESENTED AS LATE-BREAKING CLINICAL TRIAL AT HRS 2020 SCIENCE

BRIEF-Late-Breaking Clinical Trial Data Underscore Safety And Efficacy Of Boston Scientific S-ICD System

* LATE-BREAKING CLINICAL TRIAL DATA UNDERSCORE SAFETY AND EFFICACY OF BOSTON SCIENTIFIC S-ICD SYSTEM

BRIEF-Boston Scientific Q1 GAAP EPS $0.01

* Q1 SALES $2.543 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.52 BILLION

BRIEF-Boston Scientific Corp - Entered Into A New $1.25 Billion Term Loan

* BOSTON SCIENTIFIC CORP - ENTERED INTO A NEW $1.25 BILLION TERM LOAN

BRIEF-Boston Scientific Announces 2020 Annual Meeting of Stockholders Will Be Conducted in Virtual Format

* BOSTON SCIENTIFIC - 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE CONDUCTED IN VIRTUAL FORMAT IN RESPONSE TO PUBLIC HEALTH IMPACT OF CORONAVIRUS OUTBREAK Source text for Eikon: Further company coverage:

BRIEF-Nevro Says Its Patent Litigation Against Boston Scientific U.S. Court Of Appeals For Federal Circuit Issued A Ruling In Its Favor

* ITS PATENT LITIGATION AGAINST BOSTON SCIENTIFIC U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT ISSUED A RULING IN ITS FAVOR

BRIEF-FDA Says It Has Identified Boston Scientific Corp's Imager II 5F Angiographic Catheters As A Class I Recall

* FDA - HAS IDENTIFIED BOSTON SCIENTIFIC CORP'S IMAGER II 5F ANGIOGRAPHIC CATHETERS AS A CLASS I RECALL

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up